Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on STEM Times Arkansas.
Press releases published on May 23, 2025
Jitterbit Placed in 2025 Gartner® Magic Quadrant™ for Integration Platform as a Service
GlobeNewswire
·
May 23, 2025
ALAMEDA, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Jitterbit, a global leader in accelerating business transformation for enterprise systems, today announced that it has been positioned by Gartner as a Visionary in the Magic Quadrant™ for iPaaS, core to the …
Bilibili Inc. Announces Completion of US$690 Million Convertible Senior Notes and Offering of Class Z Ordinary Shares in Connection with Hedging Transactions of Certain Convertible Notes Investors and Terms of Concurrent Repurchase
GlobeNewswire
·
May 23, 2025
SHANGHAI, May 23, 2025 (GLOBE NEWSWIRE) -- Bilibili Inc. (“Bilibili” or the “Company”) (Nasdaq: BILI and HKEX: 9626), an iconic brand and a leading video community for young generations in China, today announced (i) the completion of its offering (the “ …
Huize Holding Limited to Report First Quarter 2025 Financial Results on June 6, 2025
GlobeNewswire
·
May 23, 2025
SHENZHEN, China, May 23, 2025 (GLOBE NEWSWIRE) -- Huize Holding Limited, (“Huize”, the “Company” or “we”) (NASDAQ: HUIZ), a leading insurance technology platform connecting consumers, insurance carriers and distribution partners digitally through data- …
VIRTUNE BESCHLEUNIGT EUROPÄISCHE EXPANSION MIT XRP-ETP-DEBÜT AN DER DEUTSCHE BÖRSE XETRA
GlobeNewswire
·
May 23, 2025
Frankfurt, 23. Mai 2025 – Der schwedische regulierte Krypto-Vermögensverwalter Virtune bringt eines seiner Flaggschiffproduket, den Virtune XRP ETP, an Deutschlands führenden Handelsplatz Deutsche Börse Xetra und erweitert damit sein reguliertes Angebot …
VIRTUNE ACCELERATES EUROPEAN EXPANSION WITH XRP ETP DEBUT ON DEUTSCHE BÖRSE XETRA
GlobeNewswire
·
May 23, 2025
Frankfurt, 23 May 2025 – Swedish regulated crypto asset manager Virtune brings its flagship Virtune XRP ETP to Germany's premier trading venue Deutsche Börse Xetra, extending its regulated digital asset offerings to Europe's largest economy. With strong …
Inventiva reports 2025 First Quarter Financial Information¹
GlobeNewswire
·
May 23, 2025
Cash and cash equivalents at €67.9 million Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral …
Inventiva publie ses informations financières¹ du 1er trimestre 2025
GlobeNewswire
·
May 23, 2025
Trésorerie et équivalents de trésorerie à 67,9 millions d’euros Daix (France), New York City (New York, Etats-Unis), le 23 mai 2025 – Inventiva (Euronext Paris et NASDAQ : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans …
Results of the Votes of the Combined Shareholders’ General Meeting of May 22, 2025
GlobeNewswire
·
May 23, 2025
Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic …
Résultats des Votes de l’Assemblée Générale Mixte des Actionnaires Réunies le 22 mai 2025
GlobeNewswire
·
May 23, 2025
Daix (France), New York City (New York, Etats-Unis), le 23 mai 2025 – Inventiva (Euronext Paris et NASDAQ : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la …
OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPα Blockade in Two Ongoing Trials at ASCO 2025
GlobeNewswire
·
May 23, 2025
OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPα Blockade in Two Ongoing Trials at ASCO 2025 BI 765063 in combination with programmed …
OSE Immunotherapeutics annonce que son partenaire Boehringer Ingelheim présentera des premières données cliniques issues de deux essais en cours
GlobeNewswire
·
May 23, 2025
OSE Immunotherapeutics annonce que son partenaire Boehringer Ingelheim présentera des premières données cliniques issues de deux essais en cours sur la modulation de l’immunité innée et l’activité antitumorale via le blocage de SIRPα à l’ASCO 2025 BI …
El servicio nacional Drones como un Servicio (DaaS) de ZenaTech crece con el cierre de su quinta adquisición, sumando capacidades de inspección de líneas eléctricas
GlobeNewswire
·
May 23, 2025
VANCOUVER, Columbia Británica, May 22, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ("ZenaTech"), una empresa de tecnología especializada en drones con IA (Inteligencia Artificial), Dron como un Servicio (DaaS), soluciones …
Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock
GlobeNewswire
·
May 23, 2025
SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced the pricing of its previously announced underwritten public offering of …
Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025
GlobeNewswire
·
May 23, 2025
ROCKVILLE, Md. and SUZHOU, China, May 22, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, today announced that new clinical data from two …
HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting
GlobeNewswire
·
May 23, 2025
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new data from several studies of compounds discovered by HUTCHMED including savolitinib, …